OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
National report - The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.
National report
- The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.
NICE is recommending the drug for those whom anti-tumor necrosis factor treatment is being considered and when the following criteria are both met: The disease is severe as defined by a total Psoriasis Area Severity Index of 10 or more and a Dermatology Life Quality Index of more than 10, and when the psoriasis has not responded to standard systemic therapies or if the person is intolerant of or has a contraindication to these treatments.
Related Content:
News